Navigation Links
InterMune Reports First Quarter 2013 Financial Results and Business Highlights
Date:4/24/2013

cts an estimated 3,500 to 5,000 Canadians.  Approximately one-third of IPF patients in Canada are covered by private insurance and up to six months are needed to secure coverage for new medicines from the major private insurance companies in Canada.  Public (provincial) drug reimbursement plans cover approximately two-thirds of IPF patients in Canada and, on average, about 18 months are needed to secure reimbursement from all 10 provincial governments.
  • On January 9, 2013, enrollment was completed in the confirmatory Phase 3 pirfenidone study, ASCEND, designed to support marketing approval in the United States.  ASCEND is a double-blind, placebo-controlled trial of 52 weeks duration, followed by an approximate five-week safety follow up, with a primary endpoint of change in Forced Vital Capacity (FVC) between baseline and Week 52.  The trial enrolled 555 IPF patients with mild-to-moderate impairment in lung function.  InterMune expects that top-line results from the study will be available in the second quarter of 2014.
  • On February 19, 2013, InterMune reported that the company and Shionogi & Co., Ltd had reached an agreement regarding the material terms of a settlement of the complaint filed by Shionogi against InterMune.  Effective January 1, 2013, InterMune agrees to pay Shionogi a royalty of 4.25% on net sales of Esbriet in the European Union through the remaining period of Orphan Drug exclusivity ending in February 2021.  Shionogi waives any claim against InterMune to royalties on Esbriet sales in Canada or in the United States.
  • On March 4, 2013, InterMune announced that the Pricing Commission (CPR) of the Italian Drug Agency (AIFA) had agreed to pricing and reimbursement conditions for Esbriet.  InterMune anticipates that the launch of Esbriet in Italy will begin following formal approval of the agreement by the Agency Board and publication in the Official Gazette, which is expected in
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
    8. InterMune To Release First Quarter Financial Results On April 24
    9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
    (Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
    (Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
    (Date:1/14/2014)... BioMedomics, Inc. , a Point of ... and novel disease specific POC tests, announced today that it ... total of $690,000. The investment is from private investors and ... group of private investors has significant successful experience in early ...
    Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
    ... temper tantrums lately? Or an adolescent episode of hormone-clouded ... a bit of flagging memory? , ,Given that organizations ... another, it's easy to begin thinking about organizations as ... they age. It's even understandable to want a model ...
    ... ,Jia Hu of China - Source: Getty Images The ... every four years. They're held every year. Though this is ... year as the pervasive growth of the industry becomes part ... run every four years and last two weeks, the biotech ...
    ... MADISON, Wis. - Ownership and accountability is the way ... 448-bed community hospital in Madison that provides medical care ... living facility, laboratories and a home health care service. ... Methodist Hospital in 1987, Meriter includes more than 430 ...
    Cached Biology Technology:Aging IT 2Aging IT 3The Olympics: A Biotech Perspective 2The Olympics: A Biotech Perspective 3Meriter IT team builds project performance through internal relationships 2Meriter IT team builds project performance through internal relationships 3Meriter IT team builds project performance through internal relationships 4
    (Date:7/9/2014)... are less fit in terms of cardiorespiratory capacity, ... Moreover, southern adolescents are more obese and present ... those from the centre-north of Europe. , These ... ambitious study conducted by scientists from the University ... with 25 other European research groups. The study ...
    (Date:7/9/2014)... if they are used in the right ways. ... Women,s Hospital and coauthors analyzed six use cases ... triage; decompensation (when a patient,s condition worsens); adverse ... multiple organ systems. They suspect that cost-savings benefits ... with all six scenarios will be significant. The ...
    (Date:7/8/2014)... run" or as a well-deserved break, and you,ll eat less afterward. ... you,ll later eat more dessert and snacks to reward yourself. , ... involved two studies where adults were led on a 2 km ... going to be an exercise walk or a scenic walk. ... were then given lunch. Those who believed they had been ...
    Breaking Biology News(10 mins):Adolescents from southern Europe are less fit and more obese than central-northern European peers 2The impact of big data on health care: Health Affairs' July issue 2
    ... today for the HudsonAlpha- Science 2014 Conference on ... HudsonAlpha biotechnology campus in Huntsville, Ala. The ... of this emerging scientific field. ImmunoGenomics sits at ... the use of DNA sequencing to improve disease diagnosis ...
    ... an oil spill, and images of fouled beaches and ... visible effects as well. For instance, even low levels ... fish embryos and larvae, reducing the likelihood that those ... for some time, but the underlying mechanism has remained ...
    ... by memory deficits. Basel scientists have now identified a ... is important for human brain activity, memory and the development ... online edition of the US journal Neuron . ... a telephone number - is a fundamental function of the ...
    Cached Biology News:Registration opens for HudsonAlpha-Science's 2014 Conference on ImmunoGenomics 2Registration opens for HudsonAlpha-Science's 2014 Conference on ImmunoGenomics 3Scientists discover the mechanism of heart failure in fish exposed to oil spills 2Scientists discover the mechanism of heart failure in fish exposed to oil spills 3How memory and schizophrenia are connected 2
    Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
    ...
    ...
    All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
    Biology Products: